Quentin A. Hill

Quentin A. Hill

Auto-generated profile, based on publicly available information

Quentin A. Hill

Leeds Teaching Hospitals NHS Trust Leeds UK

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2016 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
QHQuentin A. Hill
Quentin A. Hill
RSRobert Stamps
Robert Stamps
EMEdwin Massey
Edwin Massey
JGJohn D. Grainger
John D. Grainger
DPDrew Provan
Drew Provan
THThe British Society For Haematology
The British Society For Haematology

1 April 2021 in Blood
Verified
Journal Article
Closed access
PDF file
TDTina Dutt
Tina Dutt
RSRebecca J. Shaw
Rebecca J. Shaw
MSMatthew James Stubbs
Matthew James Stubbs
JYJun Yong
Jun Yong
BBBenjamin Bailiff
Benjamin Bailiff
MSMarie Scully
Marie Scully
The cornerstone of life-saving therapy in immune-mediated thrombotic thrombocytopenic purpura (iTTP) has been plasma exchange (PEX) combined with immunomodulatory strategies. Caplacizumab, a novel anti–von Willebrand factor nanobody trialed in 2 multicenter randomized controlled trials (RCTs) leading to European Union and US Food and Drug Administration approval, has been available in the United Kingdom (UK) through a patient access scheme. Data were collected retrospectively from 2018 to 2020 for 85 patients (4 children) receiving caplacizumab from 22 UK hospitals. Patient characteristics and outcomes in the real-world clinical setting were compared with caplacizumab trial end points and historical outcomes in the precaplacizumab era. Eighty-four of 85 patients received steroid and rituximab alongside PEX; 26% required intubation. Median time to platelet count normalization (3 days), duration of PEX (7 days), and hospital stay (12 days) were comparable with RCT data. Median duration of PEX and time from PEX initiation to platelet count normalization were favorable compared with historical outcomes (P < .05). Thrombotic thrombocytopenic purpura (TTP) recurred in 5 of 85 patients; all had persistent ADAMTS13 activity < 5 IU/dL. Of 31 adverse events in 26 patients, 17 of 31 (55%) were bleeding episodes, and 5 of 31 (16%) were thrombotic events (2 unrelated to caplacizumab); mortality was 6% (5/85), with no deaths attributed to caplacizumab. In 4 of 5 deaths, caplacizumab was introduced >48 hours after PEX initiation (3-21 days). This real-world evidence represents the first and largest series of TTP patients, including pediatric patients, receiving caplacizumab outside of clinical trials. Representative of true clinical practice, the findings provide valuable information for clinicians treating TTP globally.

3 April 2017 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
QHQuentin A. Hill
Quentin A. Hill
RSRobert Stamps
Robert Stamps
EMEdwin Massey
Edwin Massey
JGJohn D. Grainger
John D. Grainger
DPDrew Provan
Drew Provan
TGThe British Society For Haematology Guidelines
The British Society For Haematology Guidelines

1 November 2006 in Blood Reviews
Verified
Journal Article
Closed access
QHQuentin A. Hill
Quentin A. Hill
RORoger G. Owen
Roger G. Owen

24 June 2019 in Blood Advances
Verified
Journal Article
Open access
PDF file
QHQuentin A. Hill
Quentin A. Hill
AHAnita Hill
Anita Hill
SBSIGBJORN BERENTSEN
SIGBJORN BERENTSEN
The terminology applied to autoimmune hemolytic anemia (AIHA) seems inconsistent. We aimed to evaluate the consistency of definitions used for diagnosis and treatment. In this systematic review of literature from January 2006 to December 2015, we assessed heterogeneity in the definition of AIHA and its subtypes, refractory disease, disease phase, severity, criteria for treatment response, and response durability. A Medline search for anemia, hemolytic, autoimmune was supplemented with keyword searches. Main exclusions were conference abstracts, animal and non-English studies, and studies with <10 cases. Of 1371 articles retrieved, 1209 were excluded based on titles and abstracts. Two authors independently reviewed 10% and 16% of abstracts and full papers, respectively. After full-paper review, 84 studies were included. AIHA was most frequently (32 [52%] of 61) defined as hemolytic anemia with positive direct antiglobulin test (DAT) and exclusion of alternatives, but 10 of 32 also recognized DAT-negative AIHA. A lower threshold for diagnosis of DAT-negative AIHA was observed in literature on chronic lymphocytic leukemia. Definitions of anemia, hemolysis, and exclusion criteria showed substantial variation. Definitions of primary/secondary cold agglutinin disease/syndrome were not consistent. Forty-three studies provided criteria for treatment response, and other than studies from 1 center, these were almost entirely unique. Other criteria were rarely defined. Only 7, 0, 3, 2, 2, and 3 studies offered definitions of warm AIHA, paroxysmal cold hemoglobinuria, mixed AIHA, AIHA severity, disease phase, and refractory AIHA, respectively. Marked heterogeneity in the time period sampled indicates the need to standardize AIHA terminology.

26 June 2017 in Blood Advances
Verified
Journal Article
Open access
PDF file
JWJohn-Paul Westwood
John-Paul Westwood
MTMari Thomas
Mari Thomas
FAFerras Alwan
Ferras Alwan
VMVickie McDonald
Vickie McDonald
SBSylvia Benjamin
Sylvia Benjamin
MSMarie Scully
Marie Scully
Key Points: Rituximab is effective in preventing relapse in TTP patients in remission with low ADAMTS13 levels. Reduced-dose rituximab (200 mg) is associated with higher rates of re-treatment than the standard dose (375 mg/m2).